For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Vaccine(Chengdu Olymvax Biopharmaceuticals Inc.) | Hib conjugate vaccine Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose | None | None | 10 | 996 | 0 | 996 | View |
| Vaccine (Walvax Biotechnology Co., LTD.) | Hib conjugate vaccine Hib conjugate vaccine: Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 y:one dose(0 d), 0.5ml for each dose | None | None | 15 | 996 | 0 | 996 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| bronchopneumonia | None | Infections and infestations | None | View |
| hand-foot-and-mouth disease | None | Gastrointestinal disorders | None | View |
| pneumonia | None | Infections and infestations | None | View |
| upper respiratory tract infection | None | Infections and infestations | None | View |
| viral enteritis | None | Gastrointestinal disorders | None | View |